Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Hydrate aggressively
Your journey with GLP-1 medications is unique to you
As a result, coverage of GLP-1 drugs for the treatment of obesity remains optional for states, while coverage is required for drugs approved for the treatment of diabetes and, since March 2024 and December 2024, for the treatment of cardiovascular disease (Wegovy) and moderate to severe obstructive sleep apnea in adults with obesity (Zepbound), respectively (Table 1)
Connect with a prescriber here
US$ 23.57
US$ 23.56
US$ 20.01
US$ 26.32
